GSK Lobs False Ad Suit At Teva Over Axed Wellbutrin Generic

Law360, New York (February 11, 2013, 1:19 PM EST) -- GlaxoSmithKline LLC on Friday launched a false advertising suit in Pennsylvania federal court accusing Teva Pharmaceuticals USA Inc. of costing it hundreds of millions of dollars by promoting a generic version of antidepressant Wellbutrin that was discontinued after its effectiveness came into question.

The complaint, filed four months after Teva and Impax Laboratories Inc. yanked 300-milligram tablets of Budeprion XL from pharmacy shelves, accuses the drugmakers of concealing crucial information and stonewalling attempts to investigate reports that their medicine wasn’t yielding the same results as Wellbutrin....
To view the full article, register now.